CLC:CA:CNSX-Christina Lake Cannabis Corp (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | CNSX

Last Closing Price

CAD 0.64

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.09M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Christina Lake Cannabis Corp. engages in the growing, harvesting, processing, and sale of cannabis products in the British Columbia, Canada. It primarily offers cannabis oil, hemp oil, and other hemp and cannabis derived products. The company was formerly known as Cervantes Capital Corp. and changed its name to Christina Lake Cannabis Corp. in December 21, 2018. Christina Lake Cannabis Corp. was incorporated in 2014 and is based in Vancouver, Canada. Address: 789 West Pender Street, Vancouver, BC, Canada, V6C 1H2

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-09 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CURA:CA Curaleaf Holdings, Inc

N/A

CAD12.61B N/A 75.92
GTII:CA Green Thumb Industries Inc

N/A

CAD7.41B 484.29 39.76
TRUL:CA Trulieve Cannabis Corp

N/A

CAD6.12B 96.55 32.55
CL:CA Cresco Labs Inc

N/A

CAD3.53B N/A 43.64
TER:CA TerrAscend Corp

N/A

CAD2.32B N/A N/A
CCHW:CA Columbia Care Inc

N/A

CAD2.09B N/A N/A
PLTH:CA Planet 13 Holdings Inc

N/A

CAD1.62B N/A 215.61
HARV:CA Harvest Health & Recreation In..

N/A

CAD1.56B N/A 1,735.70
AYR-A:CA Ayr Wellness Inc

N/A

CAD1.40B N/A N/A
FFNT:CA 4Front Ventures Corp

N/A

CAD1.11B N/A N/A

ETFs Containing CLC:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -37.45% 73% C 72% C-
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets -1.44% 86% B 92% A-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.06 86% B 81% B-
Short Percent N/A N/A N/A N/A N/A
Beta 3.44 8% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike